These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 35085456)
1. A Case Report of Subanesthetic Ketamine Bolus and Infusion for Opioid Refractory Cancer Pain. Forth N; Nguyen M; Grech A J Palliat Med; 2022 Jul; 25(7):1161-1165. PubMed ID: 35085456 [TBL] [Abstract][Full Text] [Related]
2. Should Subanesthetic Ketamine be Considered When Managing Opioid Refractory Cancer Pain? Poon P; Bell RF; Good P J Pain Symptom Manage; 2024 Aug; 68(2):e146-e151. PubMed ID: 38729533 [TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Opioid-Refractory Cancer Pain with Short-Course, Low-Dose Ketamine. Waldfogel JM; Nesbit S; Cohen SP; Dy SM J Pain Palliat Care Pharmacother; 2016 Dec; 30(4):294-297. PubMed ID: 27754734 [TBL] [Abstract][Full Text] [Related]
4. Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain. Amin P; Roeland E; Atayee R J Pain Palliat Care Pharmacother; 2014 Sep; 28(3):233-42. PubMed ID: 25102039 [TBL] [Abstract][Full Text] [Related]
5. Subanesthetic ketamine in the ambulatory setting for refractory cancer pain: a 6-year retrospective at a cancer center. Chung M; Benkli B; Roldan C; Qing Y; Wang J; Huh B Pain Manag; 2021 May; 11(3):267-276. PubMed ID: 33533283 [TBL] [Abstract][Full Text] [Related]
6. The use of ketamine in the management of refractory cancer pain in a palliative care unit. Cheung KWA; Chan PC; Lo SH Ann Palliat Med; 2020 Nov; 9(6):4478-4489. PubMed ID: 31594372 [TBL] [Abstract][Full Text] [Related]
7. Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. Courade M; Bertrand A; Guerrini-Rousseau L; Pagnier A; Levy D; Lervat C; Cojean N; Ribrault A; Dugue S; Thouvenin S; Piguet C; Schmitt C; Marec-Berard P BMJ Support Palliat Care; 2022 Nov; 12(e5):e656-e663. PubMed ID: 31151954 [TBL] [Abstract][Full Text] [Related]
8. The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series. Kerr C; Holahan T; Milch R J Palliat Med; 2011 Sep; 14(9):1074-7. PubMed ID: 21838517 [TBL] [Abstract][Full Text] [Related]
9. Low-dose ketamine as an adjuvant for pain control in a cancer patient: a case report. Patel S; Tatachar V; Singh AB; Galea J; Fattakhov E; Kaur G Ann Palliat Med; 2021 Jul; 10(7):8328-8333. PubMed ID: 33615800 [TBL] [Abstract][Full Text] [Related]
10. Oral ketamine for neuropathic cancer pain. Calsina-Berna A; Alvaro Pardo M; Cucurull Salamero M; Bleda-Perez M; Julià-Torras J BMJ Support Palliat Care; 2024 Jan; 13(e3):e968-e970. PubMed ID: 37225396 [TBL] [Abstract][Full Text] [Related]
11. Topical Ketamine with Other Adjuvants: Underutilized for Refractory Cancer Pain? A Case Series and Suggested Revision of the World Health Organization Stepladder for Cancer Pain. Winegarden JA; Carr DB; Bradshaw YS J Palliat Med; 2020 Sep; 23(9):1167-1171. PubMed ID: 32167846 [No Abstract] [Full Text] [Related]
12. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. Finkel JC; Pestieau SR; Quezado ZM J Pain; 2007 Jun; 8(6):515-21. PubMed ID: 17434801 [TBL] [Abstract][Full Text] [Related]
13. Case Report: Utility of Ketamine, Lidocaine, and Mexiletine as Nonopioid Adjuvants in Complex Cancer-Associated Pain. Hakim RC; Edmonds KP; Atayee RS J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):15-19. PubMed ID: 29737933 [TBL] [Abstract][Full Text] [Related]
14. Ketamine for cancer pain: what is the evidence? Jonkman K; van de Donk T; Dahan A Curr Opin Support Palliat Care; 2017 Jun; 11(2):88-92. PubMed ID: 28306568 [TBL] [Abstract][Full Text] [Related]
15. Use of continuous intravenous ketamine for end-stage cancer pain in children. Conway M; White N; Jean CS; Zempsky WT; Steven K J Pediatr Oncol Nurs; 2009; 26(2):100-6. PubMed ID: 19202116 [TBL] [Abstract][Full Text] [Related]
16. The Enigma of Low-Dose Ketamine for Treatment of Opioid-Induced Hyperalgesia in the Setting of Psychosocial Suffering and Cancer-Associated Pain. Willeford A; Atayee RS; Winters KD; Mesarwi P J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):248-255. PubMed ID: 31125279 [TBL] [Abstract][Full Text] [Related]
17. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Grande LA; O'Donnell BR; Fitzgibbon DR; Terman GW Anesth Analg; 2008 Oct; 107(4):1380-3. PubMed ID: 18806055 [TBL] [Abstract][Full Text] [Related]
18. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. Tsui BC; Davies D; Desai S; Malherbe S J Pediatr Hematol Oncol; 2004 Oct; 26(10):678-80. PubMed ID: 15454842 [TBL] [Abstract][Full Text] [Related]
19. The effects of a multiday (10-14 days) subanesthetic dose IV ketamine infusion in the treatment of refractory chronic pain. Chebini A; Marzoughi S; Randhawa J; Guh D; Wiseman S; Fedoroff I; Ong M Pain Manag; 2022 Apr; 12(3):337-346. PubMed ID: 34528840 [TBL] [Abstract][Full Text] [Related]
20. Analgesic effect of subanesthetic intravenous ketamine in refractory neuropathic pain: a case report. Elsewaisy O; Slon B; Monagle J Pain Med; 2010 Jun; 11(6):946-50. PubMed ID: 20624244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]